Sangamo Therapeutics (SGMO) Set to Announce Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.09). Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. The company had revenue of $2.04 million for the quarter, compared to analysts' expectations of $8.96 million. On average, analysts expect Sangamo Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO traded up $0.03 during mid-day trading on Friday, reaching $0.56. The company had a trading volume of 1,179,000 shares, compared to its average volume of 2,098,082. The stock has a market capitalization of $115.33 million, a PE ratio of -0.36 and a beta of 1.40. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.67. The stock's 50 day moving average is $0.72 and its 200-day moving average is $0.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SGMO shares. StockNews.com began coverage on Sangamo Therapeutics in a research note on Saturday, April 27th. They set a "sell" rating for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. Finally, HC Wainwright reissued a "buy" rating and issued a $5.00 target price (up from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, Sangamo Therapeutics presently has a consensus rating of "Hold" and an average target price of $5.67.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.